Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Part of paid clinical trials in Palo Alto, California.

Sponsor
Qlaris Bio, Inc.
Study ID
NCT07354477
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Non-proliferative Diabetic Retinopathy (NPDR)
  • Normal Tension Glaucoma (NTG)
  • Open-angle Glaucoma (OAG)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • QLS-111 Ophthalmic Solution (0.015%) — DRUG
    QLS-111 (0.015%) administered BID for 7 days OU.
  • QLS-111 Ophthalmic Solution (0.075%) — DRUG
    QLS-111 (0.075%) administered BID for 7 days OU. Follows the 7 days where QLS-111 (0.015%) is administered.

Study Details

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Key Dates

Start date
Feb 20, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: QLS-111 Ophthalmic Solution, 2 concentrations (0.015% and 0.075%, concurrent) dosed BID for 7 days
    QLS-111 Ophthalmic Solution, 2 concentrations (0.015% and 0.075%) dosed BID for 7 days (taken 12-hour intervals) OU.

Primary Outcome Measure

Change from Baseline in blood flow to the posterior segment of the eye. [ Time Frame: Days 1 through 22 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University, Dept. of OphthalmologyPalo AltoCalifornia94303-

Find similar trials in Palo Alto, CA

By research site
Stanford University, Dept. of Ophthalmology· Palo Alto, CA

Related Studies